September 15, 2022
ProMab will be at the CAR-TCR Summit 2022 in Boston, MA! Please visit us at booth #C52 […]
March 10, 2022
Dr. Vita Golubovskaya, Director of R&D at ProMab will be hosting a webinar with Agilent that incorporates some […]
June 2, 2021
Interested in learning more about Bispecific Antibody Engineering? ProMab will be hosting a webinar encompassing our Bispecific Antibody […]
October 21, 2020
ProMab Biotechnologies is the world’s first CRO committed to improving human health with a focus on immunotherapy, specifically […]
July 28, 2020
ProMab’s humanized CD19 CAR-T platform is a CAR T-cell therapy approved for adults with treatment of relapsed and […]
February 25, 2020
BERKELEY, Calif. & RICHMOND, Calif.–(BUSINESS WIRE)–Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, […]
February 4, 2020
The 2019 novel coronavirus (2019-nCoV) is a new virus that causes respiratory illness in people and can spread […]
November 19, 2019
ProMab has recently had our work published in JoVE on the real-time cytotoxicity assay (RTCA) that we use […]
October 31, 2019
Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate For Multiple Myeloma, With An Option […]
August 21, 2019
CAR-TCR Summit 2019 Come visit the ProMab team and learn about our new products & services Booth #50 […]